In the present study, we reported the incidence of symptomatic RP (grade 2 or above) in NSCLC patients receiving first- and second-generation EGFR-TKIs and once-daily TRT, observed whether the incidence and intensity of symptomatic RP were further increased by comparing with patients receiving concurrent chemoradiotherapy (CCRT), and evaluated the usefulness of the clinical factors and DVH parameters for predicting the occurrence of asymptomatic RP. This evidence concerns the gene EGFR and non-small cell lung carcinoma.